IFLR1000

Shanghai Pharmaceuticals $144 million acquisition of Takeda Chromo

26/7/2018
Public acquisition
Select tab

$ 144 million

Announced

26/7/2018

Overview:

  • Shanghai Pharmaceuticals Holding has acquired Takeda Chromo from Tokyo-listed pharmaceutical research company Takeda Japan for $144 million.
  • The acquisition also increases Shanghai Pharmaceuticals Holding's direct and indirect shareholding in urinary protein bio-pharmaceuticals developer Techpool Bio-Pharma to approximately 67.14%.

Rajeeb Gurung - Researcher

Jurisdictions:

China
Japan
Switzerland

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firm:
Loyens & Loeff

Party: Shanghai Pharmaceuticals Holding Co Ltd (Acquirer)

Lawyer: Marco Toni

Related deals